- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | Profusa, Inc.: Profusa Shareholders Approve Strategic Initiatives at 2026 Annual Meeting, Supporting PanOmics Acquisition, Balance Sheet Strengthening and Nasdaq Compliance Efforts | 133 | GlobeNewswire (Europe) | BERKELEY, Calif., June 24, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. (Nasdaq: PFSA), a digital health company pioneering next-generation biosensing technologies, announces that shareholders approved... ► Artikel lesen | |
| Di | Profusa Aktionäre genehmigen wichtige Vorstandsvorschläge inklusive Aktienzusammenlegung | 1 | Investing.com Deutsch | ||
| PROFUSA Aktie jetzt für 0€ handeln | |||||
| Di | Profusa, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 12.06. | Profusa, Inc.: Profusa Submits Response Package to GMED as Part of Ongoing CE Mark Review Process for Lumee Oxygen Platform | 183 | GlobeNewswire (Europe) | BERKELEY, CA, June 12, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. (Nasdaq: PFSA), a digital health company pioneering next-generation biosensing technologies, today announces that it has submitted its... ► Artikel lesen | |
| 12.06. | Profusa submits response to European regulator for device approval | 2 | Investing.com | ||
| 10.06. | Profusa CEO urges shareholders to vote on Nasdaq listing proposals | 1 | Investing.com | ||
| 08.06. | Profusa, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 26.05. | Profusa, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 15.05. | Profusa, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 15.05. | Profusa moves to Nasdaq Capital Market amid compliance efforts | 1 | Investing.com | ||
| 15.05. | Profusa wechselt in den Nasdaq Capital Market, um Compliance-Anforderungen zu erfüllen | 5 | Investing.com Deutsch | ||
| 15.05. | Profusa, Inc.: Profusa Announces Listing Transfer to The Nasdaq Capital Market | 213 | GlobeNewswire (Europe) | BERKELEY, CA, May 15, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. ("Profusa" or the "Company") (Nasdaq: PFSA), a digital health company pioneering the next generation of technology platform enabling... ► Artikel lesen | |
| 08.05. | Profusa granted transfer to Nasdaq Capital Market, faces July compliance deadline | 1 | Seeking Alpha | ||
| 08.05. | Profusa, Inc.: Profusa Receives Favorable Nasdaq Listing Determination | 150 | GlobeNewswire (Europe) | BERKELEY, CA, May 08, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. ("Profusa" or the "Company") (Nasdaq: PFSA), a digital health company pioneering the next generation of technology platform enabling the... ► Artikel lesen | |
| 08.05. | Profusa, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 05.05. | Profusa, Inc.: Profusa Initiates Board-Led Process to Evaluate Strategic Alternatives and Maximize Shareholder Value | 217 | GlobeNewswire (Europe) | Company focusing resources on near-term commercial milestones; European CE Mark process and Healthcare Research revenue opportunities Process intended to evaluate strategic growth alternatives to... ► Artikel lesen | |
| 01.05. | Profusa, Inc. - S-1/A, General form for registration of securities | - | SEC Filings | ||
| 29.04. | Profusa passt Schuldenvereinbarung an und erhält Rüge von der NASDAQ | - | Investing.com Deutsch | ||
| 28.04. | Profusa, Inc. - S-1, General form for registration of securities | - | SEC Filings | ||
| 24.04. | Profusa, Inc. - 8-K, Current Report | - | SEC Filings |
1 2 3 4 Weiter >>
61 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| TELADOC HEALTH | 7,310 | -0,63 % | Teladoc Health, Inc.: Teladoc Health Reports First Quarter 2026 Results | NEW YORK, April 29, 2026 (GLOBE NEWSWIRE) -- Teladoc Health, Inc. (NYSE: TDOC), the global leader in virtual care, today reported financial results for the three months ended March 31, 2026 ("First... ► Artikel lesen | |
| HIMS & HERS HEALTH | 29,660 | -0,34 % | Hims & Hers Health, Inc. (HIMS) Sees a More Significant Dip Than Broader Market: Some Facts to Know | ||
| PLUS THERAPEUTICS | 3,650 | +2,53 % | Plus Therapeutics wins Elevance Health coverage deal | ||
| HEALWELL AI | 0,500 | +2,25 % | HEALWELL AI: HEALWELL AI Announces Voting Results of 2026 AGSM | Toronto, Ontario--(Newsfile Corp. - June 26, 2026) - HEALWELL AI Inc. (TSX: AIDX) (OTCQX: HWAIF) ("HEALWELL" or the "Company"), a healthcare artificial intelligence company focused on preventative... ► Artikel lesen | |
| ORGANON | 11,805 | -0,38 % | Organon and Henlius launch Prolia and Xgeva biosimilars in Canada | ||
| CO-DIAGNOSTICS | 3,060 | 0,00 % | Co-Diagnostics Reports First Quarter 2026 Financial Results | Advancing Global Commercialization Through CoSara Regulatory Progress and Regional Expansion
Executing Clinical Strategy with Upper Respiratory Submission Preparation... ► Artikel lesen | |
| VERU | 3,000 | -0,33 % | Top Biotech Gainers: VERU Teams Up With NVO, ABSI On Watch, ALVO Resubmits BLAs To FDA... | REYKJAVIK (dpa-AFX) - Thursday's top gainers include Veru, following a Novo Nordisk collaboration; Health Catalyst, following a divestment of its revenue workflow and analytics software business... ► Artikel lesen | |
| CLOVER HEALTH INVESTMENTS | 4,710 | -1,05 % | Jim Cramer Says Clover Health Was a Good Speculative Pick But Still Prefers UnitedHealth and CVS | ||
| SENSEONICS | 4,740 | -6,14 % | Senseonics Holdings, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results | Generated Q4 revenue of $14.3 million, an increase of 72% year-over-year Received CE Mark approval for commercialization of Eversense 365 in Europe Launched first Eversense 365 AID system integration... ► Artikel lesen | |
| ELEKTA | 4,324 | -0,37 % | Elekta AB: Elekta presents financial targets and detailed outlook ahead of Capital Markets Day | STOCKHOLM - Elekta (EKTA-B.ST) today presents new mid-term financial targets and a more detailed outlook for fiscal year (FY) 2026/2027 ahead of its Capital Markets Day in Stockholm.
Elekta is planning... ► Artikel lesen | |
| IMUNON | 1,560 | -0,64 % | Imunon, Inc.: IMUNON Announces Data Monitoring Committee Recommends Continuation of Phase 3 OVATION 3 Study Without Modification | On track for enrollment of 80 participants by Q1 2027 Trial is supported by Phase 2 results showing significant improvement in overall survival in women with newly diagnosed advanced ovarian cancer... ► Artikel lesen | |
| PERSPECTIVE THERAPEUTICS | 2,612 | 0,00 % | Perspective Therapeutics, Inc.: Perspective Therapeutics Expands Therapeutic Focus Areas; First Patient Dosed with [212Pb]VMT-a-NET in the Meningioma Cohort of a Phase 1/2a Study | SEATTLE, June 03, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective," the "Company," "we," "us," and "our") (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering... ► Artikel lesen | |
| PROCEPT BIOROBOTICS | 22,560 | 0,00 % | Evercore ISI initiates Procept BioRobotics stock with outperform rating | ||
| AXOGEN | 39,340 | -0,13 % | Axogen Hauptversammlung: Aktionäre wählen Verwaltungsrat und bestätigen Prüfer | ||
| AXE COMPUTE | 6,250 | +0,81 % | Axe Compute Inc. Reports First Quarter 2026 Financial Results and Provides Business Update | Signed $260 Million Landmark Enterprise Contract - Largest in Company History Compute Services Revenue Commenced and Customer Prepayments Grew Appointed President and CFO to Executive Leadership Team... ► Artikel lesen |
Das Unternehmen PROFUSA INC kann der Branche Gesundheitswesen zugeordnet werden. Die relative Kursveränderung beträgt aktuell -4,20 % bei einem Aktienkurs von 0,110 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu PROFUSA INC finden Sie auf Wallstreet Online.